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Chronic Myeloid Leukemia
Letícia Antunes Muniz Ferreira
Abstract
Chronic myelogenous leukemia (CML) is a chronic clonal myeloproliferative 
disease characterized by left leukocytosis, splenomegaly, and the presence of the 
Philadelphia (Ph) chromosome, which results from the reciprocal and balanced 
translocation between the long arms of chromosomes 9q34 and 22q11, generating 
the hybrid protein BCR-ABL, with increased tyrosine kinase activity. The BCR-
ABL protein is present in all patients with CML, and its hyperactivity triggers the 
release of effectors of cell proliferation and inhibitors of apoptosis, and its activity 
is responsible for the initial oncogenesis of CML. This chapter will review CML 
from its discovery, molecular and epigenetic mechanisms of disease progression to 
current treatments.
Keywords: chronic myeloid leukemia, hematologic malignancy, hematopoietic 
neoplasm, myeloproliferative disorder, Philadelphia chromosome
1. Introduction
Chronic myeloid leukemia (CML) is a neoplasm characterized by clonal expan-
sion of hematopoietic stem cells, resulting in increase of peripheral blood myeloid, 
erythroid, and platelet cells, with bone marrow (BM) myeloid hyperplasia [1, 2]. 
Typical symptoms of CML include fatigue, anorexia, and weight loss. However, 
about 40% of patients are asymptomatic, and in these patients the diagnosis is 
based on an abnormal blood count [1].
CML is categorized into three phases: chronic, accelerated, and blast crisis. At the 
beginning of the chronic phase (CP), some patients are asymptomatic, but oth-
ers have fatigue, weakness, headaches, irritability, fever, night sweats, and weight 
loss. The accelerated phase (AP) comes after a variable period of diagnosis from a 
few months to several years, and it is characterized by increased bone marrow and 
peripheral blood blasts, peripheral blood leukocytosis and basophilia, anemia and 
thrombocytopenia unrelated to treatment, or the development of cytogenetic evolu-
tion. Subsequently, the disease progresses to the blast phase (BP), defined hematolog-
ically by the increase of leukemic blasts in the peripheral blood and/or bone marrow 
(more than 20%). At this stage of the disease, many patients die within 3–6 months. 
The progression to AP and BP seems to be associated mainly with genomic instability, 
which predisposes to the appearance of other molecular abnormalities [3].
The average diagnosis of CML is 64 years. However, all age groups, including 
children, are affected. About 15% of all leukemias are CML. It is estimated for the 
USA that 1 out of 526 people will have CML in their lifetime. The American Cancer 
Society estimates for CML in the USA by 2019: about 8990 new cases will be diag-
nosed with CML (5250 in men and 3740 in women) and about 1140 CML deaths 
(660 men and 480 women) [4].
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1.1 Discovery of leukemias
The first case of leukemia was described in 1827 by Alfred Velpeau. Velpeau 
observed in a 63-year-old patient an enlarged spleen and liver associated with fever, 
weakness, and the presence of blood pus [5]. Later, Alfred Donné described the 
autopsy of a patient who had an enlarged spleen and semi-purulent blood under a 
microscope [6].
However, the first description of leukemia was credited to John Hughes Bennett 
in 1845. Bennett gave a more complete and scientific description of a 28-year-old 
patient who had postmortem examination with massive enlargement of the liver, 
spleen, and lymph nodes, in addition to the presence of purulent blood [7]. In the 
same year, Rudolf Virchow described the autopsy of a 50-year-old female patient 
with splenomegaly and pus in her blood vessels [8].
In 1852, Bennett described 37 cases of leucocythemia [9]. Later, in 1856, Virchow 
noted that cases of splenomegaly leukemia had some granular blood cells with irregular 
or divided nuclei, while patients with lymphadenopathy already had smooth nucleus 
cells [10]. Virchow proposed two main varieties of chronic leukemia, splenic and 
lymphatic, which today are identified as leukemia and lymphoma, respectively [11].
The introduction of blood cell staining techniques in 1878 by Paul Ehrlich revo-
lutionized hematology, allowing a differentiation of different types of leukocytes 
[12]. With this, Ehrlich distinguished lymphoid and myeloid leukemias [13].
1.2 Discovery of Philadelphia chromosome
The improvement of cytogenetic techniques allowed the study of chromosomal 
arrangements in various pathological conditions. Thus, specific human disorders 
were found to be associated with specific chromosomal abnormalities (e.g., Down 
syndrome, associated with an extra copy of chromosome 21) [14].
In 1960, Peter Nowell and David Hungerford identified a small chromosome in 
two CML patients. This chromosome was called the Philadelphia (Ph) chromosome, 
according to the chromosome standardization committee, which suggested that 
abnormal chromosomes be designated by the name of the city in which they were 
discovered [11, 14, 15]. The discovery of this chromosome was a very important step 
in understanding the pathophysiology of CML.
Chromosome banding techniques revolutionized the cytogenetic approach. 
Thanks to this advance in 1973, Janet Rowley demonstrated that the Ph chromosome 
was not a simple deletion but a reciprocal and balanced translocation between the 
long arms of chromosomes 9 and 22 [16]. Still in the 1970s, Herbert Abelson and 
Louise Rabstein identified the ABL gene, located on chromosome 9, position 9q34 
[11]. Protein tyrosine kinase ABL is related to the processes of regulation of cell 
proliferation, survival, cell adhesion, and migration [17].
In 1984, Groffen et al., through the cloning of genomic DNA from CML patients, 
identified chromosome breaks within a limited region on chromosome 22, which 
they called the breakpoint cluster region (BCR) [18, 19]. Thus, the highly specific 
presence of the BCR chromosome breakpoint in patients with Ph-positive CML 
strongly suggested the involvement of this gene in leukemia.
In the formation of the Ph chromosome, the ABL1 proto-oncogene (Abelson 
leukemia 1) is translocated from chromosome 9 to the BCR gene on chromosome 
22 at position 22q11. This process gives rise to the chimeric BCR-ABL1 gene, which 
encodes a constitutively active protein tyrosine kinase, considered central in 
the mechanism involved in chronic phase-chronic myeloid leukemia (CP-CML) 
[20–22]. Identification of this anomaly is extremely important for the diagnosis of 
the disease and for treatment purposes.
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1.3 Variants of Ph chromosome
The Ph is detected by G-band karyotyping in around 90% of CML patients 
among whom 5–10% may have variant chromosome types [23–25]. Variants of 
Ph chromosome are characterized by the involvement of another chromosome 
in addition to chromosomes 9 and 22. Variant rearrangements can be simple or 
complex. Simple-type variants involve another chromosome, for example, t (9; 22; 
6). Complex variants participate in the translocation of two or more chromosomes, 
besides chromosomes 9 and 22 [26, 27].
Variant Ph breakpoints occur in hotspots across the genome, usually in the G-light 
bands, within the cytosine and guanine (CG) richest parts of the genome [28]. CG 
content correlates with chromatin condensation and transcription activity; that is, 
open chromatin is transcriptionally active and relatively likely to undergo breakage and 
repair with a consequent tendency to illegitimate recombination and translocation [24].
Variant Ph chromosomes are distinguished from additional chromosomal abnor-
malities or clonal evolution that drives disease progression. The clonal evolution is a 
reflection of a genetic instability that characterizes the transition to advanced phase 
[29]. However, the mechanism of variant Ph generation and the molecular bases of 
biological differences between classic Ph and variant Ph chromosomes are not fully 
understood [30].
In atypical CML (aCML), patients are Ph-negative. This leukemia presents 
initial characteristics and clinical course similar to those of Ph-positive patients. 
However, Ph-negative patients have more heterogeneous characteristics, often more 
aggressive disease progresses with worse prognosis [31].
2. Molecular characterization of CML
The BCR-ABL fusion protein with strong tyrosine kinase activity is one of the 
molecular biological bases of leukemia [32]. The Ph chromosome is generated by 
the translocation t (9; 22) (q34; q11). The normal c-ABL gene is located on chro-
mosome 9 and has 11 exons (1b, 1a, a2–a11). During chromosomal translocation, 
c-ABL gene breakdown can occur at three points: upstream of 1b, between 1b and 
1a, and between 1a and a2. Regardless of the breakpoint, the first two alternative 
exons (1b and 1a) are always separated [21].
The normal BCR gene is located on chromosome 22 and consists of 23 exons (e1–
e23). In generation of the BCR-ABL fusion gene, there are three breakpoints that 
can occur in the BCR gene: major (M-BCR), minor (m-BCR), and micro (μ-BCR). 
The M-BCR break can generate junctions e14a2, e13a2, e14a3, and e13a3; m-BCR 
breakdown can induce junctions e1a2 and e1a3; and the breakdown in μ-BCR can 
give rise to e19a2 junction [21].
Despite the many junctions that exist, in Ph-positive hematological neoplasms, 
the junctions e14a2 and e13a2 are the most frequent. These two junctions generate 
the same transcript encoding the p210 BCR-ABL protein. The junction e19a2 pro-
duces a transcript encoding the p230 BCR-ABL protein. And junction e1a2 creates a 
transcript that encodes p190 BCR-ABL [21, 29].
All domains of c-ABL protein—SRC-homology-2 (SH2) domain, SH3 domain, 
tyrosine kinase domain, nuclear localization signal (NLS), nuclear export signal 
(NES), DNA-binding domain (DBD), and actin-binding domain (ABD)—are 
present in the three BCR-ABL proteins. However, the three BCR-ABL proteins have 
different BCR domains [33].
The SH2 and SH3 regulatory domains mediate protein-protein interactions and 
control activation of transduction signals. The SH3 domain is known as a negative 
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regulator of kinase activity, acting as a counterpoint to the SH2 domain, inactivat-
ing its tyrosine kinase-activating and receptor potential [34]. In BCR-ABL products, 
a partial or complete deletion of the SH3 domain occurs, losing negative control. 
In contrast, the SH2 domain is eventually activated by the presence of a tyrosine 
kinase-activating component [35].
The BCR-ABL fusion protein acts as an oncoprotein by activating several signal-
ing pathways that lead to transformation. Myc, Ras, c-Rafn MAP/ERK, SAPK/JNK, 
STAT, NFKB, PI-3kinase, and c-Jun are included as signal cascade molecules. Many 
signaling proteins have been shown to interact with BCR-ABL through various 
functional domains and/or to become phosphorylated in BCR-ABL-expressing 
cells. In brief, BCR-ABL activates the main signal pathways, such as RAS/MAPK, 
PI-3kinase, c-ABL pathways and CRKL pathways, and JAK-STAT, and the Src 
pathway to play a major role in transformation and proliferation. Inhibition of 
apoptosis is thought to result from activation of the PI-3 kinase and RAS pathways 
with induction through AKT of Myc and BCL-2 [36].
Activation of these signaling pathways leads to deregulation of cellular processes 
such as proliferation, differentiation, DNA repair, decreased adhesion of leukemic 
cells to bone marrow stroma, and reduced apoptotic response to mutagenic stimula-
tion, leading to uncontrolled clonal proliferation [37].
3. Diagnostic of CML
Approximately 40% of patients are asymptomatic, and the diagnosis is made 
with a blood count [1], performed by any clinical situation, preoperatively or even 
at a checkup. Several methodologies may be employed for the diagnosis of CML 
patients, including microscopic examination of peripheral blood and bone marrow, 
cytogenetics, and molecular biology.
3.1 Blood count
In peripheral blood of patients with CML, there is a leukocytosis of approxi-
mately 225,000/mm3 ranging from 20,000 to 600,000/mm3 and an intense increase 
in circulation granulocytes. Granulocytosis is characterized by a small proportion 
of leukemic blasts and promyelocytes and predominance of intermediate forms 
(such as myelocytes and metamyelocytes), in addition to maturing and fully mature 
neutrophils (rods and segmented). Differential leukocyte count shows staggered 
left shift from mature neutrophils to myeloblasts. Fifteen to 20% proportions of 
basophils may be found [1, 37].
The presence of mild anemia and thrombocytosis are also common in CML. There 
is a small correlation between hemoglobin concentration and the total number of 
white blood cells (hemoglobin values range from 9.7 g/dL ranging from 5.4 to 14.4 g/
dL). Depending on the stage of the disease, the number of platelets ranges from 
485,000/mm3, ranging from 25,000 to 1,400,000/mm3. Basophilia and eosinophilia 
are common findings. Leukocyte alkaline phosphatase is generally low and can be 
used to distinguish CML from other myeloproliferative diseases [1, 37, 38].
3.2 Myelogram
Analysis of bone marrow (BM) through myelogram reveals granulocytic hyper-
plasia, leading to a leukoerythroblastic ratio of 20:1. The differentiation sequence is 
maintained, however with a predominance of younger cells such as promyelocytes 
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and myelocytes. The number of megakaryocytes is increased. Other nonspecific 
biopsy findings include reticulin fibrosis and vascularization [1, 37].
3.3 Cytogenetics
The cytogenetic picture of CML provides unique and crucial information for 
diagnosis. Cytogenetic analysis of bone marrow or peripheral blood cells allows 
the identification of the Ph translocation and other chromosome changes that are 
associated with the leukemic process. Diagnostic assays at baseline for CML patients 
are based on the standard banding cytogenetics (chromosome banding analysis or 
CBA) and fluorescence in situ hybridization (FISH) [39].
Cytogenetic examination is preferably performed on bone marrow cells. The 
t (9; 22) (q34; q11) is easily recognized when the cell cycle of leukemic cells is 
disrupted in the metaphase. Identification of translocation 9; 22 requires analysis of 
at least 20 metaphases [40].
The FISH technique is used when the result is urgent. Fast and specific, this 
technique allows detection of BCR-ABL rearrangement through the use of molecu-
lar probes [37].
3.4 Molecular biology
The most modern and effective methods for detecting BCR-ABL transcripts are 
based on molecular biology techniques. Polymerase chain reaction (PCR) testing of 
peripheral blood RNA is highly sensitive: it can detect 1 Ph-positive cell expressing 
the BCR-ABL fusion transcript in 105–106 normal cells [1].
Real-time PCR is a great ally of clinical oncologist seeking better therapeutic 
outcomes because it helps in defining treatment, which can be more or less aggres-
sive according to each patient’s response [41]. Importantly, molecular methods, 
although extremely sensitive, do not allow observation of concomitant gene or 
chromosomal alterations.
4. Treatment of CML
Therapy for treatment of CML developed very slowly. Heinrich Lissauer, in 1865, 
described the use of arsenic in two leukemia patients [42], nothing new in view of 
the fact that the use of arsenic for cancer therapy had been described in the Indian 
Ramayana more than 2000 years earlier [43].
In the 1920s, radiotherapy entered clinical practice, and it was soon used for the 
treatment of CML, and for over 50 years, radiotherapy was considered the standard 
treatment. Radiation was usually directed to the spleen for symptomatic relief 
[43–45].
After the Second World War, there was the rapid development of alkylating 
agents. Thus, busulfan largely replaced radiotherapy in the 1960s. Later, hydroxy-
urea (hydroxycarbamide) was introduced in the USA (United States of America). 
Prospective studies showed that patients treated with hydroxyurea survived longer 
than those treated with busulfan. However, it was not clear whether this was due to 
the beneficial effect of hydroxyurea or a mitogenic effect of busulfan [44].
In the early 1980s, interferon-α (IFN-α) was introduced for the treatment of 
CP-CML. Few patients achieved any level of Ph-negative hematopoiesis, and others 
achieved a complete and lasting Ph-negative hematopoiesis. In rare cases, IFN-α 
may be discontinued without subsequent relapse. Thus, IFN-α replaced busulfan 
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and hydroxyurea in the treatment of CP-CML if the patient was not eligible for 
allogeneic BM transplantation [46].
In 1979, Fefer and colleagues treated four CP-CML patients with high doses 
of chemoradiotherapy, followed by transfusion of stem cells from their geneti-
cally identical twins [47]. At follow-up intervals of 22–31 months, these patients 
remained well absent of Ph-positive metaphases in their marrow. The previously 
fatal leukemia brought the possibility of treatment and cure through BM transplan-
tation [45].
Researchers began to treat CP-CML patients with allogeneic BM transplanta-
tion between identical HLA siblings. In the beginning, conditioning consisted of 
the use of cyclophosphamide and full body irradiation. However, years later, it 
was decided to use busulfan with cyclophosphamide [48]. According to the Center 
for International Blood & Marrow Transplant Research, allograft-associated 
transplant-related mortality for CP-CML patients is about 10–20% at 1 year, and the 
survival at 5 years is about 60% [49]. Most survivors have no evidence of leukemia, 
but occasional patients relapse early after transplantation [44].
Thus, from the 1990s, the treatment of choice for all relatively young CP-CML 
patients (under 50 years old) was an allogeneic stem cell transplant (SCT). In 
France, patients with CML who were not eligible for allograft were treated with 
IFN-α plus cytarabine [50], although more recent data from Italy cast doubt on this 
conclusion [51].
4.1 Tyrosine kinase inhibitors
Accumulated knowledge of action mechanism of BCR-ABL was sufficient to 
initiate experiments with target molecule designs to be used in the treatment of 
CML. From the knowledge that tyrosine kinase is the effective portion of onco-
protein, it was evident that its inhibition would be the most attractive target as a 
therapeutic strategy. The goal was to design a small chemical compound that would 
compete with ATP binding at the kinase domain site. Thus, with this site occupied 
by an “ATP-like” molecule, it would not be possible to provide any phosphate 
group for substrate transfer. With this, the tyrosine residues would remain in the 
“non-phosphorylated” form, and the protein substrate would not be able to change 
its conformation so that it could be associated with the effectors described above, 
resulting in the interruption of oncogenetic signals to the nucleus of cell.
This “ATP-like” molecule, known as imatinib, revolutionized the treat-
ment in oncology and specifically of CML, opening the “era of targeted specific 
therapy.” One of the first studies on the effectiveness of imabinib treatment (the 
International Randomized Study of Interferon and STI571 [IRIS] trial) estimated 
the rate of complete cytogenetic response (CCyR) at 12 months in the imatinib 
arm was 69%. Such responses are in relation to the standard treatment of the time 
(IFN-α and cytarabine) [52].
One of the last IRIS updates showed an estimated overall survival (OS) rate of 
83% at 10 years (20.1% of patients had unknown survival status when data was ana-
lyzed). It should be mentioned that, despite these excellent results, 31 and 52% of 
patients assigned to imatinib discontinued treatment by 5 and 10 years of follow-up, 
respectively. The main cause of treatment discontinuation was the unsatisfactory 
therapeutic effect (11%), while only 4% of patients discontinued treatment due to 
side effects [53].
Treatment with imatinib induces a hematological response in 90% of patients 
diagnosed in the CP and a cytogenetic response in 80% of them, which made bone 
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marrow transplantation, the only curative treatment for CML, to be indicated only 
in those patients who develop imatinib resistance, observed in 20–25% of cases [52].
Known mechanisms of imatinib resistance include the presence of mutation 
point in the BCR-ABL tyrosine kinase domain, amplification of the BCR-ABL gene, 
overexpression of the multidrug resistance gene known as P-glycoprotein, and low 
expression of pickup transporters such as SLC22A1 (hOCT1) [54].
The second generation TKIs (2GTKIs), dasatinib, nilotinib, and bosutinib, were 
initially approved in CML patients who were resistant or intolerant to imatinib. Due 
to a more potent in vitro inhibition of the unmutated BCR-ABL kinase with a good 
safety profile, these second generation TKIs were later evaluated and approved in 
the first-line setting [55].
Dasatinib is an oral, second generation TKI that is 350 times more potent than 
imatinib in vitro. It also inhibits the Src family of kinases, which may be important 
in blunting critical cell signaling pathways [56]. Compared to the structure analog 
of imatinib, nilotinib’s affinity for the ATP-binding site on BCR-ABL1 is 30–50 
times more potent in vitro [57]. Like dasatinib, nilotinib initially demonstrated the 
ability to induce hematologic and cytogenetic responses in patients who had failed 
imatinib [56]. Bosutinib appeared to retain activity across most known mutations 
that confer imatinib resistance, except for T315I. Responses were independent of 
whether patients had resistance to or intolerance of imatinib [56].
A subset of patients with CML exhibited either primary or secondary resistance 
to imatinib. Primary resistance refers to patients never responding to imatinib, 
whereas secondary resistance occurs when a patient who had an initial response 
to imatinib eventually loses the response [36]. Although a significant proportion 
of patients respond to 2GTKI therapy after imatinib failure, most of them (70%, 
approximately) will eventually discontinue such treatment in the short term due to 
loss of response or toxicity [55].
There are many treatment mechanisms of resistance, and several of them, 
mostly in vitro or in selected patient samples, have been reported. However, their 
individual contribution to this phenomenon has not been completely defined. The 
most frequently identified mechanism of resistance is the development of muta-
tions in the ABL tyrosine kinase domain [55].
A third generation TKI, ponatinib, is approved in CML patients with refractory 
CML or Ph-positive acute lymphoblastic leukemia (Ph + ALL) and those harboring 
the BCR-ABL1T315I mutant [58]. Clinical trials using the approved dose of 45 mg/
day of ponatinib show the main concern with this drug is the increased incidence of 
cardiovascular complications [55]. Table 1 shows the target recommendations for 
CML, according to the American Cancer Society.
First generation TKI CML patients newly diagnosed
Second generation TKI CML patients resistant or intolerant to imatinib
Third generation TKI CML patients with refractory CML or Ph-positive acute lymphoblastic 
leukemia and those harboring the BCR-ABL1T315I mutant
Interferon or chemotherapy CML patients who cannot take TKI or those who are not responding to 
treatment
Allogeneic stem cell 
transplantation
CML who have failed at least two TKIs and for all patients in advanced 
phase disease
Table 1. 
Target recommendations for CML [4].
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4.1.1 Definition of therapeutic response
The quality of response to TKI treatment is categorized according to the labo-
ratory method used. Patients are monitored by hematological, cytogenetic, and 
molecular response, and their terminology has been standardized by the European 
Leukemia Net [59].
Hematologic response is defined by the presence of platelets <450 × 109L, 
without differential immature granulocytes and <5% basophils, and a non-palpable 
spleen. Cytogenetic response (CyR) is defined according to the proportion of 
positive Philadelphia chromosome (Ph +) in bone marrow cells. The association 
between CyR and improved survival made the cytogenetic response the gold stan-
dard of CML therapy [36]. Table 2 shows the cytogenetic response definition.
The IRIS study, conducted in 2003, defined two types of molecular response 
assessed by real-time PCR: major molecular remission (MMR) and complete 
molecular remission (CMR). Major molecular remission is defined as a three-log 
drop of the initial load of BCR-ABL at the time of diagnosis; this value is equal to 
or less than 0.1%. Complete molecular remission is defined when the BCR-ABL 
transcript is undetectable [60].
Response to treatment is monitored during the first 3 months through clinical 
evaluation, blood count, and biochemical exams every 2 weeks. After the third 
month, cytogenetics is recommended every 6 months until complete CCyR is 
achieved. From the moment the patient reaches CCyR (Ph + 0%), monitoring is 
performed through real-time PCR quarterly to detect minimal residual disease [61].
4.2 Allogeneic stem cell transplantation
For patients who fail frontline therapy, the second-line options include sec-
ond and third generation TKIs. Even though second and third generation TKIs 
are potent and selective TKIs, some patients still do not respond to treatment. 
Allogeneic stem cell transplantation (allo-SCT) remains an important therapeutic 
option for patients with CML-CP who have failed at least two TKIs and for all 
patients in advanced phase disease [56].
Patients exposed primarily to TKI treatment do not respond negatively to allo-
SCT. Conversely, if patients referred for transplant have the lower CML burden, 
they may respond better to allo-SCT [62].
Allo-SCT is the only treatment with healing potential. However, it remains 
associated with substantial risks of morbidity and mortality. For appropriate coun-
selling of patients, a rapid and simple way to assess risk is needed [63]. Pre-allo-SCT 
risk factors for CML are donor type, disease stage, recipient age, recipient-donor 
gender combination, and, lastly, time between diagnosis and allo-SCT. Table 3 
presents the risk factors for allo-STC [63–67].
Complete cytogenetic response (CCyR) 0% Ph-positive metaphases
Partial cytogenetic response (PCyR) 1–35% Ph-positive metaphases
Minor cytogenetic response (mCyR) 36–65% Ph-positive metaphases
Minimal cytogenetic response (min CyR) 66–95% Ph-positive metaphases
No response (NR) >95% Ph-positive metaphases
Table 2. 
Cytogenetic response definition [59].
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In the era of TKIs, there is no doubt for the first-line treatment for CML patients. 
But when allo-SCT is indicated, this scoring system is still of great value in estimat-
ing overall disease-free survival and procedure-related mortality.
When considering allo-SCT for CML patients, it is important to know that a 
poor response to one or more TKIs does not predict a negative transplant response. 
TKIs pharmacologically block BCR-ABL activity, while allo-SCT depends on graft-
versus-leukemia (GVL) effect [68].
The challenge of allo-SCT for treatment of leukemia and other malignan-
cies of the hematopoietic system is the prevention of graft-versus-host disease 
(GVHD) without losing the GVL effect. Depletion of T cells abrogates GVHD 
and GVL effects. Delayed transfusion of donor lymphocytes into chimeras after 
T-cell-depleted stem cell transplantation produces a GVL effect without necessarily 
producing GVHD [69].
Allo-SCT should not be seen as a last resort but as a treatment strategy to be 
considered viable at the beginning of treatment for patients who have suboptimal 
responses to TKIs. The key issues for HSCT in CML are those of patient selection, 
risk stratification, and outcome optimization by means of regimen selection and 
improved supportive care [68].
5. Conclusions
CML is a myeloproliferative disease, resulting from clonal expansion of hema-
topoietic progenitor stem cells, characterized by BCR-ABL fusion gene, resulting 
from reciprocal translocation t (9; 22) (q34; q11) that gives rise to Ph chromosome. 
All the accumulated knowledge about action mechanisms of BCR-ABL1 has enabled 
the development of very efficient target-specific drugs, as well as molecular meth-
ods for disease monitoring.
Allo-SCT is a possible cure for CML; however, it is associated with mortality 
and morbidity increased due to complications in the pre- and posttransplantation 
periods, such as GVHD, immunosuppression, and multiple organ toxicity.
Prognostic factors Score
Donor type 0—related identical human leukocyte antigen (HLA)
1—unrelated identical HLA
Disease stage 0—chronic phase (CP)
1—accelerated phase (AP)
2—blast phase (BP)
Receiver age 0—< 20 age
1—20–40 age
2—> 40 age
Gender donor/receiver 1—female/male
0—male/female
Time from diagnosis to transplant 0—< 12 months
1—> 12 months
Table 3. 
Risk factors for allo-STC [63–67].
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Although great progress has been made for the improvement in clinical treat-
ment during the past decades, it is common for patients to develop resistance to 
treatments. Therefore, further exploring the novel therapeutic strategies is still 
crucial for improving disease outcome.
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